Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Shuffles Execs; Roche Taps New Dx Head; CuraGen Promotes Finigan; and Others

NEW YORK (GenomeWeb News) - Helicos shuffled some executives this week, with company co-founder and CEO Stanley Lapidus taking on the job of chairman from Noubar Afeyan and Stephen Lombardi moving up to the role of president while retaining his job as COO. Afeyan was named lead independent director on the company’s board. 
Lombardi was previously COO and vice president of Helicos. Prior to joining the company, he was a senior VP at Affymetrix and before that he spent 16 years at Applied Biosystems as an executive in the company’s DNA sequencing and genetic analysis business. 

Jürgen Schwiezer will become CEO of Roche Diagnostics on Jan. 1, 2008. He will succeed Severin Schwan, who will take over the role of CEO of the Roche Group from Franz Humer in March.
Schwiezer is currently president of the Europe, Middle East, and Africa regions for Roche Diagnostics. He joined Boehringer Mannheim in 1976 and held a number of management positions in marketing and sales. That firm was acquired by Roche in 1997.
Schwiezer also will serve on Roche’s corporate executive committee. 

CuraGen has appointed Paul Finigan as executive VP and general counsel, the company said in a filing with the US Securities and Exchange Commission. Finigan has been senior VP and general counsel since the summer of 2006. In his new role, Finigan will have the added responsibilities for managing company business development, on top of his legal and IP work.
The filing did not disclose the company’s plans for current executive VP, CFO and treasurer, Daniel Wurzer

Assay Designs has named Michael Mullenix to the post of VP of research and development and Gabriella Szekely-Klepser as VP of science and technology.
Mullenix previously was at Amgen, where he was principal scientist in clinical immunology, and he has held leadership roles at Molecular Staging, Becton Dickinson, and Strategic Diagnostics.
Szekely-Klepser has been an associate research fellow at Pfizer Global R&D, and she has held various R&D roles at 3M Corporation.  

Wafergen has appointed Sharat Singh senior VP of research and development and Christopher Maki as VP of worldwide sales.
Singh was previously chief scientific officer at Aclara Biosciences, where he worked in the development of gene expression and protein analysis assays, as well as other personalized medicine areas.
Maki previously was director of sales, research imaging, and high-content screening at Molecular Devices. Prior to that, he was a regional sales manager at Universal Imaging and a researcher at the Vollum Institute for Advanced Biomedical Research and at the University of Pennsylvania.  

BioForce NanoSciences has appointed Michael Dunham to its board of directors. Dunham previously was on the board of directors at Arryx Technology. He is chairman and owner of Workwise and Intercim, and he previously was senior VP of business development for Industrial & Financial Systems and was co-founder and CEO of Effective Management Systems.  

Gene Express has appointed David Lester as senior VP of strategy and corporate development. Lester previously worked as New York site head for Pfizer’s global clinical technology business, and he was founder and director of Pfizer Human Health Technologies.
Lester also was a director of clinical technologies for experimental medicine at Pharmacia, and was a senior service advisor to the Office of Pharmaceutical Sciences and an associate director and team leader at the US Food and Drug Administration.  

Clarient this week said it has tapped Michael Pellini to step in as interim COO for a term the company expects to last into the second quarter of 2008.
The company also said that Karen Garza, who is senior VP of strategic planning and business development, and Jose de la Torre-Bueno, who is senior VP and CTO, will leave the company “following an interim period of transitional consulting.”
Pellini will retain his post as VP of Life Sciences at Safeguard Scientifics and will remain on Clarient’s board of directors, Clarient said.
Prior to joining Safeguard, Pellini was COO at Lakewood Pathology Associates and an entrepreneur in residence at BioAdvance.
From 1999 to 2004, Pellini served as president and CEO of Genomics Collaborative

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.